These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6670591)

  • 41. Myelography with the non-ionic water-soluble contrast medium metrizamide.
    Hindmarsh T
    Acta Radiol Diagn (Stockh); 1975 Sep; 16(5):417-35. PubMed ID: 1199781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparison of the side-effects of iohexol and metrizamide in lumbar myelography/radiculography].
    Lesak F
    Ugeskr Laeger; 1986 May; 148(20):1206-8. PubMed ID: 3727099
    [No Abstract]   [Full Text] [Related]  

  • 43. A prospective comparison of iotrolan, iohexol and iopamidol for lumbar myelography.
    Lamb J; McAllister V; Nelson M; Bartlett R; Smith I; Deopugari CE
    Acta Radiol Suppl; 1986; 369():524-7. PubMed ID: 2980547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Side effects after lumbar iohexol myelography. Relation to radiological diagnosis, sex and age.
    Sand T; Myhr G; Stovner LJ; Dale LG
    Neuroradiology; 1990; 31(6):523-8. PubMed ID: 2352635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experimental study of arachnoiditis from iohexol, an investigational nonionic aqueous contrast medium.
    Haughton VM; Ho KC; Lipman BT
    AJNR Am J Neuroradiol; 1982; 3(4):375-7. PubMed ID: 6810669
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose iohexol myelography.
    Simon JH; Ekholm SE; Kido DK; Utz R; Erickson J
    Radiology; 1987 May; 163(2):455-8. PubMed ID: 3562826
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive and affective changes after myelography: a comparison of metrizamide and iohexol.
    Ratcliff G; Sandler S; Latchaw R
    AJR Am J Roentgenol; 1986 Oct; 147(4):777-81. PubMed ID: 3489380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A randomized, double-blind clinical trial of 2 nonionic contrast media for myelography].
    Lovrencić M; Klanfar Z; Jakovac I
    Lijec Vjesn; 1986 Apr; 108(4):141-6. PubMed ID: 3520199
    [No Abstract]   [Full Text] [Related]  

  • 49. Myelography with Omnipaque (Iohexol) using basic radiographic facilities: the main adverse effects.
    Ndosi BN; Ndosi NK; Kazema RR
    Cent Afr J Med; 1996 Jul; 42(7):192-5. PubMed ID: 8936782
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of metrizamide and iohexol for cisternal myelographic examination of dogs.
    Puglisi TA; Green RW; Hall CL; Read WK; Green RA; Tangner CH; Mann FA; Hobson HP
    Am J Vet Res; 1986 Aug; 47(8):1863-9. PubMed ID: 3530068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myelography with a dimeric (iodixanol) and a monomeric (iohexol) contrast medium: a clinical multicentre comparative study.
    Skalpe IO; Bonneville JF; Grane P; Gyldenstedt C; Otto B; Kristoffersen DT; Svaland MG
    Eur Radiol; 1998; 8(6):1054-7. PubMed ID: 9683718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neural tissue uptake and clearance of iohexol following lumbar myelography in rabbits.
    Ekholm SE; Foley M; Morris TW; Sahler L
    Acta Radiol Diagn (Stockh); 1985; 26(3):331-6. PubMed ID: 4013823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metrizamide as contrast medium for myelography and ventriculography. Preliminary clinical experiences.
    Gonsette RE
    Acta Radiol Suppl; 1973; 335():346-58. PubMed ID: 4549779
    [No Abstract]   [Full Text] [Related]  

  • 54. Adverse effects of lumbar myelography with amipaque and dimer-X.
    Irstam L; Selldén U
    Acta Radiol Diagn (Stockh); 1976 Mar; 17(2):145-59. PubMed ID: 1274652
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Absorption of iohexol from cerebrospinal fluid to blood: pharmacokinetics in humans.
    Olsson B; Eldevik OP; Grønnerød TA
    Neuroradiology; 1985; 27(2):172-5. PubMed ID: 3838805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safer lumbar myelograms--the search continues.
    Mason K
    Can Nurse; 1983 Jun; 79(6):28. PubMed ID: 6552927
    [No Abstract]   [Full Text] [Related]  

  • 57. Tolerability of iohexol after injection into healthy volunteers.
    Levorstad K; Kolbenstvedt A; Kolmannskog F; Sommerfelt SC; Stormorken H; Andrew E; Sveen K
    Acta Radiol Diagn (Stockh); 1983; 24(3):241-51. PubMed ID: 6624528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tolerability and usefulness of iohexol in cardioangiography. I. An open multicentre clinical trial.
    Levorstad K; Simonsen S; Skrede M; Orning O; Tylén U; Olsson L; Selin K; Dahlström K; Andrew E
    Acta Radiol Diagn (Stockh); 1982; 23(6):535-43. PubMed ID: 6763454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metrizamide--CSF contrast medium. Analysis of clinical application in 215 patients.
    Sackett JF; Strother CM; Quaglieri CE; Javid MJ; Levin AB; Duff TA
    Radiology; 1977 Jun; 123(3):779-82. PubMed ID: 860047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myelography with iohexol (Omnipaque); a clinical report with special reference to the adverse effects.
    Skalpe IO; Nakstad P
    Neuroradiology; 1988; 30(2):169-74. PubMed ID: 3386812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.